[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"surgical-procedures-operative\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:surgical-procedures-operative":35},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,53,93,141,169,202,222,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100172884","product-surveillance-registry-100172884",false,"NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results","ALL",{"count":19,"type":20},100000,"ESTIMATED","OBSERVATIONAL","The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Coronary Artery Disease","Ear, Nose and Throat Disorder","RECRUITING","2026-06-15",{"date":43,"type":44},"2026-06-17","ACTUAL",{"date":46,"type":4},"2012-01",{"date":48,"type":20},"2040-01",{"name":50,"class":51},"Medtronic","INDUSTRY",395,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":67,"conditions":68,"keywords":73,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":92},"100638709","prehabilitation-before-major-surgery-100638709","NCT07590141","Prehabilitation Before Major Surgery","PRehabilitation In Advance of Major Elective Surgery: A Pilot Randomized Controlled Trial (PRIME Pilot)","PRIME","Inclusion Criteria:\n\n* ≥ 18 years of age\n* Undergoing major elective intra-thoracic, intra-abdominal or orthopedic surgery. Major surgery is defined as any operation performed under general and\u002For spinal anesthesia requiring a skin incision extending beyond the subcutaneous tissue\n* More than 3 weeks from the date of scheduled operation\n\nExclusion Criteria:\n\n* Emergency Surgery\n* Operation in less than 3 weeks from time of initial research contact\n* Patients who are pregnant\n* Unable\u002Funwilling to sign written informed consent\n* Physical, cognitive or psychological impairment\n* Unable to understand\u002Fcommunication in English.","18 Years",{"count":63,"type":20},120,"INTERVENTIONAL",[66],"NA","The goal of this clinical trial is to learn if a virtually monitored, home-based prehabilitation program is feasible and acceptable for adults undergoing major elective surgery. The main questions it aims to answer are:\n\n1. Can researchers successfully recruit and retain participants across multiple sites?\n2. Will participants adhere to the prehabilitation program at a high enough rate to justify a larger trial?\n\nResearchers will compare the prehabilitation program to standard preoperative care to see if the intervention is feasible to implement and whether it may help reduce postoperative complications.\n\nParticipants will:\n\n* Be randomly assigned to receive either the prehabilitation program or usual care\n* Complete questionnaires and physical assessments before and after the intervention\n* (For those in the intervention group) Receive exercise, nutrition, and mindfulness guidance, protein supplements, and use the CloudDX virtual care platform to support their activities",[69,70,71,72,35],"Prehabilitation","Preoperative Care","Elective Surgical Procedures","Postoperative Complications",[74,75,76,77,78,79,80],"Home-based Care","Virtual Care","Remote Health Monitoring","Exercise Therapy","Nutritional Support","Psychological Support","Postoperative Outcomes","NOT_YET_RECRUITING","2026-05-10",{"date":84,"type":44},"2026-05-15",{"date":86,"type":20},"2026-06-01",{"date":88,"type":20},"2028-01-31",{"name":90,"class":91},"Queen's University","OTHER",3,{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":99,"eligibilityCriteria":100,"healthyVolunteers":11,"sex":17,"minAge":101,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":104,"conditions":105,"keywords":122,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":136,"leadSponsor":138,"locationsCount":140},"100625999","saudi-emergency-laparotomy-audit-100625999","NCT07429929","Saudi Emergency Laparotomy Audit","Saudi Emergency Laparotomy Audit (SELA): A National Multicenter Observational Audit of Outcomes Following Emergency Laparotomy in Saudi Arabia","SELA","Inclusion Criteria:\n\n* Age ≥14 years\n* Undergoing an emergency (E1-E4) laparotomy, laparoscopy, or laparoscopically-assisted abdominal operation\n* Procedures involving the stomach, small bowel, large bowel, or rectum for acute pathology (e.g., perforation, ischemia, abscess, bleeding, or obstruction)\n* Washout\u002Fevacuation of intra-peritoneal abscess or hematoma (excluding those secondary to appendicitis or cholecystitis)\n* Bowel resection or repair for obstructed\u002Fincarcerated hernias with acute presentation (incisional, umbilical, inguinal, femoral)\n* Adhesiolysis (open or laparoscopic)\n* Trauma-related emergency abdominal procedures\n* Inoperable pathology where a definitive operative procedure was intended (not purely diagnostic)\n* Return to theatre for major wound dehiscence (\"burst abdomen\")\n* Complications requiring general surgical intervention following interventional radiology procedures\n* Complications requiring general surgical intervention following gynecological oncology surgery\n* Complications following elective or non-elective general\u002Fupper GI surgery, where the above criteria are met\n\nExclusion Criteria:\n\n* Age \\\u003C14 years\n* Elective laparotomy or laparoscopy\n* Diagnostic-only laparotomy or laparoscopy (unless abandoned due to inoperable disease)\n* Appendicectomy or cholecystectomy (including their complications), unless incidental to a more major non-elective gastrointestinal procedure\n* Non-elective hernia repair without bowel resection or adhesiolysis\n* Minor wound dehiscence repair (unless bowel resection is required)\n* Stoma formation via trephine or laparoscopic approach (include only if midline laparotomy is the primary procedure)\n* Vascular, obstetric, gynecological (except gynecological oncology complications requiring general surgery input), transplant, hepatobiliary, urological, renal, pancreatic, or splenic procedures","14 Years",{"count":103,"type":20},10000,"The Saudi Emergency Laparotomy Audit (SELA) is a national, multicenter observational clinical audit designed to evaluate outcomes and quality of care for patients undergoing emergency laparotomy in Saudi Arabia. The audit will collect standardized data on patient characteristics, comorbidities, perioperative processes, and postoperative outcomes through a retrospective baseline phase followed by a prospective registry phase. SELA aims to establish national benchmarks, assess applicability of international risk models, support development of a Saudi-specific risk prediction tool, and drive quality improvement through systematic feedback and benchmarking across participating hospitals.",[106,107,108,109,110,111,112,113,114,115,116,117,118,119,120,35,121],"Laparotomy","Laparotomy Surgery","Emergency Treatment","Abdominal Diseases","Gastrointestinal Diseases","Intestinal Obstruction","Intestinal Obstruction and Ileus","Intestinal Perforation","Intestinal Ischemia","Peritonitis Infectious, Gastrointestinal Perforation, Surgical Infection, Postoperative Complications","Peritonitis Bacterial","Peritonitis Caused by Perforated Left-sided Colon Diverticulitis","Peritonitis Infectious","Sepsis","Postoperative Complications After Gastrointestinal Operations","Mortality",[123,124,125,126,121,127,128,129,130,131],"Emergency laparotomy","Surgical audit","Postoperative outcomes","Perioperative care","Morbidity","Quality improvement","Risk stratification","Retrospective audit","Saudi Arabia","2026-02-22",{"date":134,"type":44},"2026-02-24",{"date":86,"type":20},{"date":137,"type":20},"2028-12-31",{"name":139,"class":91},"King Faisal Specialist Hospital & Research Center",1,{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":64,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":168},"100563841","a-national-study-examining-the-most-effective-drainage-method-after-burr-hole-evacuation-of-chronic-subdural-hematoma-100563841","NCT06621407","A National Study Examining the Most Effective Drainage Method After Burr Hole Evacuation of Chronic Subdural Hematoma","Active 24 Hours Subperiostal vs. 24 Hours Passive Subdural Drainage Following Burr Hole Evacuation of Chronic Subdural Hematoma (the SUPERDURA Trial) - Protocol for a Nationwide Randomized Clinical Non-inferiority Trial","SUPERDURA","Inclusion Criteria:\n\n* Adult patients (≥ 18 years).\n* Patients with symptomatic CSDH confirmed on brain CT- or magnetic resonance imaging (MRI), admitted to a Danish neurosurgical department for surgical treatment.\n* Patients undergoing a single burr-hole evacuation.\n* Informed written and oral consent is taken prior to surgery.\n\nExclusion Criteria:\n\n* Patients who are mentally incapacitated\n* Patients with known abnormalities in their cerebrospinal fluid (protein and glucose levels, cell count, and type)\n* Patients with changes or abnormalities in their normal cerebrospinal fluid dynamics, e.g., obstructive hydrocephalus, normal pressure hydrocephalus, intracranial hypotension, and ventricular peritoneal shunt.\n* Patients with additional\u002Fpreviously intracranial pathology that requires\u002Fhas required neurosurgical treatment (e.g., brain tumor, vascular malformation, abscess).\n* Patients with recurrent CSDH or with previous craniotomy or other transcranial surgery (for any reason)\n* Patients unable to give consent prior to surgery",{"count":150,"type":20},354,[66],"Chronic subdural hematoma (CSDH) is a common disease. The main treatment is neurosurgical evacuation and subsequent hematoma drainage. However, consensus on the optimal drain placement site, and whether the drainage should be active or passive, is lacking.\n\nThe aim of the current study is to test the hypothesis that 24 hours active subperiosteal drainage is non-inferior to 24 hours passive subdural drainage after single burr hole evacuation of a unilateral CSDH.\n\nThe study is a multicenter randomized non-inferiority trial encompassing all neurosurgical units in Denmark.\n\nAdult patients with symptomatic CSDH admitted to a Danish neurosurgical unit for single burr hole evacuation will be screened for inclusion. Patients who are not able to give informed consent, and patients with recurrent CSDH, known cerebrospinal fluid abnormalities, and other known brain pathologies will be excluded. Patients with bilateral CSDH will be registered as one case and treated similarly on both sides.\n\nBefore surgical hematoma evacuation patients will be randomized to 24-hour passive subdural drainage or 24-hour active subperiosteal drainage.\n\nThe patients included and the two study statisticians will be blinded. The primary outcome is a composite outcome of 90-day mortality and symptomatic CSDH recurrence.\n\nSecondary outcomes are 90-day simplified modified Rankin score (smRSq), and complications related to surgery or occurring during admission, including intracerebral hemorrhage due to misplaced drains, acute subdural hematoma, tension pneumocephalus, wound infection, drain seepage, subperiosteal hematoma, thromboembolic events, infections and seizures.\n\nSample size simulations of non-inferiority with a threshold of 7% increased relative risk show that a total of 354 participants will be required to demonstrate a relative risk reduction of recurrent CSDH and mortality of 30% for the cohort receiving active subperiosteal drainage given a stable power above 80% with an alpha of 5%. The study inclusion period is estimated to last 2 years.\n\nEthics approval for inclusion of competent patients has been obtained (N-20240009).",[154,35,155,121,156,157,158],"Chronic Subdural Hematoma","Recurrence","Drainage","Drainage\u002FMethods","Drainage Procedure","2025-11-20",{"date":161,"type":44},"2025-11-25",{"date":163,"type":44},"2025-09-01",{"date":165,"type":20},"2027-11",{"name":167,"class":91},"Aalborg University Hospital",4,{"id":170,"slug":171,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":177,"minAge":61,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":64,"phases":181,"briefSummary":182,"conditions":183,"keywords":188,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":4},"100599049","eit-evaluation-of-pulmonary-ventilation-with-different-ropivacaine-concentrations-in-intercostal-nerve-blockade-100599049","NCT07079436","EIT Evaluation of Pulmonary Ventilation With Different Ropivacaine Concentrations in Intercostal Nerve Blockade","Electrical Impedance Tomography (EIT) to Evaluate the Effect of Different Concentrations of Ropivacaine on Pulmonary Ventilation Function During Intercostal Nerve Blockade","EIT","Inclusion Criteria:\n\n* Patients scheduled for elective breast quadrantectomy;\n* Aged 18-80 years;\n* American Society of Anesthesiologists (ASA) physical status I-II;\n* Body mass index (BMI) \\\u003C35 kg\u002Fm².\n\nExclusion Criteria:\n\n* Contraindications for nerve block: infection at the puncture site, local anesthetic allergy, coagulation dysfunction or bleeding risk;\n* Patients with unilateral diaphragmatic paralysis;\n* Patients with severe ventilatory or gas exchange dysfunction;\n* Complicated with acute or chronic pulmonary and bronchial diseases, sleep apnea syndrome;\n* Mental disorders;\n* Patients who refuse to participate;\n* Patients whom the researchers consider unsuitable for the clinical trial, with reasons to be specified.","FEMALE","80 Years",{"count":180,"type":20},72,[66],"This study aims to find out how different strengths of the anesthetic drug ropivacaine affect lung breathing function when used in intercostal nerve block (a type of local anesthesia) for breast quadrantectomy surgery. Researchers will use a non-invasive imaging technique called electrical impedance tomography (EIT) to monitor lung ventilation in real time.\n\nWhy is this study being done? Intercostal nerve block is a common anesthesia method for breast surgeries, but the ideal strength of ropivacaine that balances effective pain relief with safety for lung function is not fully clear. EIT can help measure how each drug strength affects breathing by showing changes in lung airflow.\n\nWhat will happen in the study? Participants: 72 adults scheduled for breast quadrantectomy, aged 18-80, will be randomly assigned to receive one of three ropivacaine strengths (0.25%, 0.375%, or 0.5%) during intercostal nerve block.\n\nProcedures: After anesthesia, EIT will monitor lung ventilation before and after the block. Researchers will measure:\n\nHow much each lung side contributes to breathing during quiet and deep breaths. How quickly the anesthesia works, pain levels during surgery, and any side effects (like difficulty breathing or allergic reactions).\n\nWho can join? Adults having elective breast quadrantectomy. ASA physical status I-II (generally healthy to mildly ill). BMI \\\u003C35 kg\u002Fm². No history of nerve block allergies, breathing problems, or certain lung diseases.\n\nWhat are the possible benefits? The study may help doctors choose the best ropivacaine strength to ensure good pain control while minimizing risks to lung function, especially for same-day surgery patients.\n\nWhat are the risks? Potential risks include rare side effects from the anesthetic (like allergic reactions or low blood pressure) or temporary breathing changes, which will be closely monitored.\n\nHow is the study designed? This is a double-blind, randomized trial (neither patients nor doctors know which drug strength is used) at Fudan University Shanghai Cancer Center.",[184,185,186,187,35],"Intercostal Nerve Block","Pulmonary Ventilation","Anesthesia, Local","Breast Neoplasms",[189,184,190,191,192,187],"Ropivacaine","Pulmonary Ventilation Function","Electrical Impedance Tomography","Anesthetic Concentration","2025-07-22",{"date":195,"type":44},"2025-07-23",{"date":197,"type":20},"2025-08-10",{"date":199,"type":20},"2025-12-31",{"name":201,"class":91},"Fudan University",{"id":203,"slug":204,"hasResults":11,"nctId":205,"briefTitle":206,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":211,"conditions":212,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":213,"lastUpdatePostDateStruct":214,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":140},"100571755","detection-of-health-risk-situations-in-the-anesthesia-consultation-100571755","NCT06724380","Detection of Health Risk Situations in the Anesthesia Consultation.","Inclusion Criteria:\n\n* Men and women aged 18 to 50 years.\n\n  * Indication for elective surgery.\n  * In-person preoperative evaluation in the scheduled Anesthesiology consultation.\n\nExclusion Criteria:\n\n* Indication for non-deferrable urgent surgery.\n* Pregnant women.\n* Pre-surgical visit outside the anesthesia consultation.\n* Incomplete preoperative evaluation, as indicated in the final section (preoperative judgment) of the anesthesia visit report.","50 Years",{"count":210,"type":20},218,"This study aims to estimate the proportion of patients seen in the anesthesiology consultation for planned surgery in whom a previously unknown health risk situation is detected (e.g., obesity, anemia, etc.).",[35],"2025-02-10",{"date":215,"type":44},"2025-02-12",{"date":217,"type":44},"2025-02-04",{"date":219,"type":20},"2025-12",{"name":221,"class":91},"Consorci Sanitari de l'Alt Penedès i Garraf",{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":228,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":232,"conditions":233,"keywords":238,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":140},"100572802","national-emergency-bariatric-surgery-audit-100572802","NCT06738004","National Emergency Bariatric Surgery Audit","A National Multi-centre Prospective Audit of Unplanned Surgical and Endoscopic Interventions in Patients Who Have Undergone Bariatric Surgery in the UK or Abroad","NEBSA","Inclusion Criteria:\n\n* Admissions from i) the emergency department, clinic, urgent care or primary care to the bariatric surgical team as an emergency; ii) from an inpatient team as an urgent referral; iii) a return to theatre following an elective bariatric procedure; iv) another hospital via patient transfer to a specialised unit.\n* Participants undergoing any intervention or procedure to treat or diagnose bariatric complications, (e.g., OGDs, interventional radiology, surgery, supplemental enteral or parenteral nutrition).\n\nExclusion Criteria:\n\n* age \\\u003C18 years old\n* have a length of stay \\\u003C24 hrs.\n* initial diagnosis of BSE is changed or if their readmission is found to be unrelated to previous bariatric surgery.",{"count":231,"type":20},500,"The goal of this observational study is to investigate the incidence, management, and outcomes of complications following bariatric surgery in patients in the United Kingdom. The main questions it aims to answer are:\n\n* What is the prevalence of unplanned interventions due to complications following bariatric surgery in the UK?\n* What are the current practices for managing these complications, and how do they impact patient outcomes?\n\nParticipants will:\n\nBe identified from hospitals treating patients presenting with complications following bariatric surgery.\n\nHave their data collected regarding demographics, surgical history, complications, treatments, and outcomes.\n\nResearchers will compare different management strategies and their impact on patient outcomes, with the aim of identifying best practices to improve emergency bariatric care and factors leading to patients attending as an emergency.",[234,72,235,35,236,237,127,121],"Bariatric Surgery","Emergencies","Outcome Assessment (Health Care)","Quality Improvement",[239,240,241,242,243,244,245,128,246,247],"Bariatric surgery","Emergency complications","National audit","Surgical outcomes","Management strategies","United Kingdom","Patient safety","Morbidity and mortality","Postoperative complications","2024-12-12",{"date":250,"type":44},"2024-12-17",{"date":252,"type":44},"2023-11-09",{"date":254,"type":20},"2025-12-09",{"name":256,"class":91},"Bedfordshire Hospitals NHS Foundation Trust",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":261,"acronym":4,"eligibilityCriteria":262,"healthyVolunteers":263,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":264,"targetDuration":4,"studyType":64,"phases":266,"briefSummary":268,"conditions":269,"keywords":272,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":275,"lastUpdatePostDateStruct":276,"startDateStruct":278,"completionDateStruct":280,"leadSponsor":282,"locationsCount":140},"100455501","phase-3-comparisons-of-metabolic-effect-of-sleeve-gastrectomy-with-duodenojejunal-bypass-and-sleeve-gastrectomy-medusa-a-multicenter-randomized-controlled-trial-100455501","NCT05211375","Comparisons of Metabolic Effect of Sleeve Gastrectomy With Duodenojejunal Bypass and Sleeve Gastrectomy (MEDUSA): A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* Age over 18 years\n* BMI equal to or greater than 27.5 kg\u002Fm2\n* T2DM duration ≤ 10 years\n* Using insulin, or HbA1c ≥ 7.0% while taking diabetes medication\n* C-peptide level higher than 1.0 ng\u002FmL\n* Presence of type 2 diabetes fulfilling the following criteria\n* Consent to not become pregnant for at least 1 year after surgery\n* Willingness to provide voluntary informed consent\n\nExclusion Criteria:\n\n* Presence of uncontrolled severe gastroesophageal reflux (LA classification C or more in esophagogastroduodenoscopy)\n* History of previous metabolic surgery for T2DM\n* History of gastrointestinal surgery, such as gastrectomy or anti-reflux surgery, which may affect the result of metabolic surgery\n* Therapy regimen of more than 3 psychiatric drugs owing to poorly controlled psychiatric disorders\n* Suicidal attempts within the last 12 months\n* Treatment for alcohol and drug abuse within the last 12 months\n* Vulnerability factors (lacking mental capacity, pregnancy or planning of pregnancy, lactation)\n* Unsuitability as per the discretion of the researcher",true,{"count":265,"type":20},130,[267],"PHASE3","In this study, the effects of SG with DJB and SG alone for the treatment of type 2 diabetes mellitus (T2DM) will be compared in patients other than the two groups at both extremes who are expected to show excellent effects of metabolic surgery with SG alone (mild T2DM) and who need SG with DJB (severe T2DM).\n\nThis study is to target patients with poor blood sugar control despite current medical treatment, although the beta-cell function of the pancreas is preserved. Therefore, this study is aimed at patients who have been using insulin for less than 10 years with T2DM, or taking diabetic medications with HbA1c ≥ 7.0% for less than 10 years with T2DM.\n\nThe investigators hypothesize that the treatment effects of SG with DJB for T2DM will be superior to that of SG in this group",[270,234,35,271],"Diabetes Mellitus, Type 2","Asians",[234,273,274],"Metabolic Surgery","Diabetes Remission","2022-01-13",{"date":277,"type":44},"2022-01-27",{"date":279,"type":44},"2022-01-03",{"date":281,"type":20},"2036-01-03",{"name":283,"class":91},"Seoul National University Bundang Hospital"]